North Chicago, USA; Hørsholm, Denmark – March 3, 2025: Through a strategic alliance with Denmark-based company Gubra A/S (CPSE: GUBRA), which specializes in preclinical contract research and peptide-based medication discovery, globally biopharmaceutical company AbbVie (NYSE: ABB) has formally entered the obesity treatment space. The development of GUB014295, a new long-acting amylin analog with potential to revolutionize obesity control, is the main emphasis of the cooperation.
Currently under Phase 1 clinical trials, GUB014295 is being investigated as a potential candidate to treat obesity, a disorder afflicting around 900 million adults globally. Acting as an agonist, the medication activates calcitoninin and amylin receptors, both of which are very vital for control of appetite. GUB014295 seeks to enable patients better control their weight by boosting signals that induce satiety and slowing down stomach emptying.
Robert A. Michael, Chief Executive Officer of AbbVie, said the business is dedicated to revolutionizing patient care, particularly in areas with notable unmet medical need. As we enter the obesity market, our alliance with Gubra signals a significant turning point. Michael noted that AbbVie has a great chance to significantly improve patient life and simultaneously propel long-term development.
One of the most urgent worldwide health issues still is obesity, since many people find it difficult to sustain weight loss with current treatments. The Executive Vice President of Research & Development and Chief Scientific Officer of AbbVie, Roopal Thakkar, M.D., underlined the importance of creative solutions. “Given Gubra’s experience in peptide-based therapeutics, we are optimistic about the potential of GUB01429 in offering a more effective solution for obesity management,,” he said.
Henrik Blou, CEO of Gubra, also showed excitement about the partnership. “AbbVie has a great history of creating and bringing to market ground-breaking drugs. Our collaboration will hasten the progress of GUB01429 and leverage the encouraging results of the Phase 1 single ascending dose (SAD) experiment. Working with a team as dedicated as AbbVie’s in delivering this treatment to patients excites us,” Blou said.
Under the deal, AbbVie will oversee the worldwide commercialization and development of GUB014295. Gubra might earn up to $1.875 billion in extra payments depending on development, commercial, and sales benchmarks in addition to an initial payment of $350 million. Additionally included in the agreement are tiered royalties on worldwide net sales. Standard closing conditions and regulatory clearances still control completion of the deal.
Conducted at a single center, the two-part, double-blind, placebo-controlled Phase 1 clinical trial of GUB01429 While Part 2, which investigates several ascending doses, is currently under progress, Part 1—which comprised single ascending doses—has been finished. The official clinical trials registry under the identification NCT06144 provides further information regarding the trial.
